KNOTUS Co.Ltd (278650) - Total Liabilities

Latest as of September 2025: ₩44.24 Billion KRW ≈ $29.98 Million USD

Based on the latest financial reports, KNOTUS Co.Ltd (278650) has total liabilities worth ₩44.24 Billion KRW (≈ $29.98 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore KNOTUS Co.Ltd (278650) equity growth momentum to track the company's year-over-year net asset growth rate.

KNOTUS Co.Ltd - Total Liabilities Trend (2016–2024)

This chart illustrates how KNOTUS Co.Ltd's total liabilities have evolved over time, based on quarterly financial data. See KNOTUS Co.Ltd free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

KNOTUS Co.Ltd Competitors by Total Liabilities

The table below lists competitors of KNOTUS Co.Ltd ranked by their total liabilities.

Company Country Total Liabilities
SNC Former Public Company Limited
BK:SNC
Thailand ฿7.70 Billion
Multicampus Corporation
KQ:067280
Korea ₩94.82 Billion
XAC Automation
TWO:5490
Taiwan NT$458.60 Million
Positivo Tecnologia S.A
SA:POSI3
Brazil R$2.84 Billion
CareCloud, Inc.
NASDAQ:CCLD
USA $28.39 Million
Quantum Foods Holdings
JSE:QFH
South Africa ZAC1.08 Billion
Black Diamond Therapeutics Inc
NASDAQ:BDTX
USA $28.62 Million
Railcare Group AB (publ)
ST:RAIL
Sweden Skr846.25 Million

Liability Composition Analysis (2016–2024)

This chart breaks down KNOTUS Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of KNOTUS Co.Ltd.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.29 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.41 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.28 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how KNOTUS Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for KNOTUS Co.Ltd (2016–2024)

The table below shows the annual total liabilities of KNOTUS Co.Ltd from 2016 to 2024.

Year Total Liabilities Change
2024-12-31 ₩56.45 Billion
≈ $38.26 Million
-17.15%
2023-12-31 ₩68.14 Billion
≈ $46.18 Million
-33.14%
2022-12-31 ₩101.91 Billion
≈ $69.06 Million
+239.26%
2021-12-31 ₩30.04 Billion
≈ $20.36 Million
+46.02%
2020-12-31 ₩20.57 Billion
≈ $13.94 Million
+4.60%
2019-12-31 ₩19.67 Billion
≈ $13.33 Million
-14.76%
2018-12-31 ₩23.07 Billion
≈ $15.64 Million
+38.33%
2017-12-31 ₩16.68 Billion
≈ $11.30 Million
+49.28%
2016-12-31 ₩11.17 Billion
≈ $7.57 Million
--

About KNOTUS Co.Ltd

KQ:278650 Korea Biotechnology
Market Cap
$96.91 Million
₩143.01 Billion KRW
Market Cap Rank
#19231 Global
#916 in Korea
Share Price
₩1693.00
Change (1 day)
+6.95%
52-Week Range
₩1099.00 - ₩4785.00
All Time High
₩36886.01
About

HLB bioStep Co.,Ltd. provides various test services in South Korea. It offers non clinical CRO services for cancer, bone and brain disease, endocrineand metabolic and eye disease, liver and circulatory system disease, dental and gastrointestinal disease, hair growth, kidney and respiratory disease, painmodel, and skin disease. It also offers representative analysis equipment, veterinary drug deve… Read more